NO p16(INK4A)/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas

Journal of Pathology

Volumn 184, Issue 1, 1998, Pages 14-17

  Meye, Axel ^a   Würl, Peter ^a   Hinze, Raoul ^a   Berger, Dieter ^a   Bache, Matthias ^a   Schmidt, Hannelore ^a   Rath, Friedrich Wilhelm ^a   Taubert, Helge ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Immunohistochemistry; Liposarcoma; MFH; p16(INK4A) CDKN2 MTS1 CDK4I; PCR SSCP sequencing; Soft tissue tumours

Indexed keywords

ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; DRUG ANTAGONISM; GENETICS; METABOLISM; MUTATION; SARCOMA; SOFT TISSUE TUMOR;

CYCLIN DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; TUMOR PROTEIN;

CYCLIN-DEPENDENT KINASES; GENES, P16; GENES, P53; HUMANS; MUTATION; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RETINOBLASTOMA PROTEIN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0031596871     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199801)184:1<14::AID-PATH957>3.0.CO;2-K     Document Type: Article

References (27)

1. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 85: 841-954.
2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704-707.
3. INK4A. Cancer Res 1994; 54: 5816-5820.
4. INK4A in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
5. Merlo A, Herman JG, Mao L, et al. 5′-CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1: 686-692.
6. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumour types. Science 1994; 264: 436-440.
7. Cairns P, Mao L, Merlo A, et al. Rates of p16 (mts1) mutations in primary tumours with 9p loss. Science 1994; 265: 415-417.
8. Liu Q, Neuhaussen S, McClure M, et al. CDKN2 (MTS1) tumour suppressor gene mutations in human tumour cell lines. Oncogene 1995; 10: 1061-1067.
9. Mealandsmo GM, Berner J-M, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas. Br J Cancer 1995; 72: 393-398.
10. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996; 86: 136-142.
11. Dei-Tos AP, Maestro R, Doglioni C, et al. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996; 148: 1037-1045.
12. Naumann M, Savitskaia N, Eilert C, Schramm A, Kalthoff H, Schmiegel W. Codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumours. Gastroenterology 1995; 110: 1215-1224.
13. Taubert H, Würl P, Meye A, et al. Molecular and immunohistochemical status in liposarcoma and malignant fibrous histocytoma. Cancer 1995; 76: 1187-1196.
14. Iolascon A, Faienza MF, Coppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chrom Cancer 1996; 15: 217-222.
15. Beltinger CP, White PS, Sulman EP, Maris JM, Brodcur GM. No CDKN2 mutations in neuroblastomas. Cancer Res 1995; 55: 2053-2055.
16. Kawamata N, Seriu T, Koeffler HP, Bartram CR. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16 (CDKN2/MTS1/INK4A). p18 (INK4C) and p27 (Kip1) genes in neuroblastomas. Cancer 1996; 77: 570-575.
17. Dicciani MB, Chau LS, Batova A, Vu TQ, Yu AL. The p16 and p18 tumor suppressor genes in neuroblastoma: implication for drug resistance. Cancer Lett 1996; 104: 183-192.
18. Raffel C, Ueki K, Harsh GR, Louis DN. The multiple tumour suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumour, Neurosurgery 1995; 36: 971-975.
19. INK4A cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995; 87: 1870-1875.
20. Xiao S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995; 11: 511-515.
21. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547-5555.
22. Jagasia AA, Block JA, Qureshi A, et al. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumour suppressor genes in human chondrosarcomas. Cancer Lett 1996; 105: 91-103.
23. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with mdm2 and GLI in human sarcomas. Cancer Res 1993; 53: 5535-5541.
24. 1 control. Cancer Res 1995; 55: 4818-4823.
25. Taubert H, Meye A, Würl P. Prognosis is correlated to p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996; 56: 4134-4136.
26. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen-induced tumourigenesis in p53-deficient mice. Nature Genet 1993; 5: 225-229.
27. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DcPinho RA. Role of the INK4a locus in tumour suppression and cell mortality. Cell 1996; 85: 27-37.